ACP: Switching From Dulaglutide to Tirzepatide Improves HbA1c Reduction in T2DM

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, April 4, 2025 -- For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with escalating treatment with dulaglutide, according to a study published online April 4 in the Annals of Internal Medicine to coincide with the Internal Medicine Meeting, the annual meeting of the American College of Physicians, held from April 3 to 5 in New Orleans.

Liana K. Billings, M.D., from the Pritzker School of Medicine at the University of Chicago, and colleagues conducted a multicenter, randomized, phase 4 trial to compare the efficacy and safety of escalation of dulaglutide dose versus switching to tirzepatide in inadequately controlled type 2 diabetes. A total of 828 adults with HbA1c 7.0 percent or greater to 9.5 percent or less, stable body weight, and body mass index of 25 kg/m2 or greater receiving a stable dose of dulaglutide (0.75 or 1.5 mg) for at least six months were randomly assigned to tirzepatide or escalation of dulaglutide (139 and 143, respectively).

The researchers found that at week 40, the change from baseline in HbA1c was −1.44 and −0.67 percent with tirzepatide and dulaglutide escalation to 4.5 mg or maximum tolerated dose, respectively. The change from baseline in weight at week 40 was −10.5 and −3.6 kg with tirzepatide and dulaglutide, respectively. Overall, 7.2 and 7.0 percent of tirzepatide- and dulaglutide-treated patients, respectively, had serious adverse events. Nausea and diarrhea were the most common treatment-emergent adverse events reported.

"Once-weekly treatment with tirzepatide resulted in significantly greater HbA1c and weight reductions compared with continuing and escalating dulaglutide treatment," the authors write.

The study was funded by Eli Lilly, the manufacturer of tirzepatide.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-04-05 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords